Biotech Gainers: ImmuCell Corporation (NASDAQ:ICCC), Applied Genetic Technologies Corp (NASDAQ:AGTC), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), Sorrento Therapeutics Inc. (NASDAQ:SRNE), Alder Biopharmaceuticals Inc. (NASDAQ:ALDR)

ImmuCell Corporation (NASDAQ:ICCC) announced on 14 may Product sales for the three-month period ended March 31, 2014 increased by 13%, or $235,000, to $2,082,000 from $1,847,000 during the same period in 2013. ImmuCell Corporation (NASDAQ:ICCC) net profit margin is 1.60% and weekly performance is 14.49%. On last trading day company shares ended up $4.74. Analysts mean target price for the company is $-. ImmuCell Corporation (NASDAQ:ICCC) distance from 50-day simple moving average (SMA50) is 14.12%.

BMO Capital Markets boosted their price target on shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) from $21.00 to $34.00 in a research note issued on Monday. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 34.44% from the stock’s previous close. Applied Genetic Technologies Corp (NASDAQ:AGTC) shares advanced 6.26% in last trading session and ended the day on $27.49. AGTC return on assets is -60.40%.

TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) announced that it will host a conference call and live audio webcast on Monday, June 16, 2014 at 08:00 a.m. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) shares moved up 8.79% in last trading session and was closed at $5.82, while trading in range of $5.34 – $5.89. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) year to date (YTD) performance is -38.87%.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, on 12 June announced that the underwriters of its previously announced underwritten public offering of 4,765,000 shares of its common stock have exercised in full their option to purchase an additional 714,750 shares of common stock from the Company at $5.25 per share to cover over-allotments, bringing total gross proceeds from this offering to approximately $28,768,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The offering of these additional shares is expected to close on or about June 16th, 2014, subject to customary closing conditions. Sorrento Therapeutics Inc. (NASDAQ:SRNE) ended the last trading day at $5.43. Company weekly volatility is calculated as 5.62% and price to cash ratio as 5.05.Sorrento Therapeutics Inc. (NASDAQ:SRNE) showed a positive weekly performance of 4.42%.

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) quiet period will end on Tuesday, June 17th. Alder Biopharmaceuticals had issued 8,000,000 shares in its IPO on May 8th, American Banking and Market News reports. The total size of the offering was $80,000,000 based on an initial share price of $10.00. Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) weekly performance is 29.39%. On last trading day company shares ended up $20.34. Analysts mean target price for the company is $23.00. Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) distance from 50-day simple moving average (SMA50) is 70.02%.